← Back to patent-cliff list
APT-5031
Tier C — Watch / tradeAPT-5031
Adare Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：中枢神经系统紊乱
Regional status
US
-
EU
Phase III
2018-01-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of APT-5031?
Approved indications include: 中枢神经系统紊乱.
When does the APT-5031 patent expire?
No public expiry year is available for APT-5031 yet; this page updates once verified.
How do I get a quote for APT-5031 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09